Tomomi Okubo
A5049568375- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatitis B Virus Studies
- Colorectal Cancer Treatments and Studies
- Liver Disease and Transplantation
- Cancer, Lipids, and Metabolism
- Cancer Mechanisms and Therapy
- Lung Cancer Treatments and Mutations
- HIV/AIDS drug development and treatment
- Cancer Immunotherapy and Biomarkers
- Inflammatory Biomarkers in Disease Prognosis
- Economic and Financial Impacts of Cancer
- Radiomics and Machine Learning in Medical Imaging
- Liver physiology and pathology
- Diabetes Treatment and Management
- Systemic Lupus Erythematosus Research
- Vitamin D Research Studies
- Diet, Metabolism, and Disease
- Gastric Cancer Management and Outcomes
- Nutrition and Health in Aging
- Metabolism, Diabetes, and Cancer
- Lymphoma Diagnosis and Treatment
Nippon Medical School
2015-2025
Chiba Hokusou Hospital
2016-2025
Second Affiliated Hospital of Xi'an Jiaotong University
2024
Kaohsiung Medical University
2024
National Sun Yat-sen University
2024
Kagawa Prefectural Central Hospital
2023
AstraZeneca (Brazil)
2023
Bayer (Finland)
2023
Gifu Kyoritsu University
2023
Himeji Red Cross Hospital
2023
A growing body of evidence suggests that non-viral hepatocellular carcinoma (HCC) might benefit less from immunotherapy.We carried out a retrospective analysis prospectively collected data consecutive patients with advanced HCC, treated atezolizumab plus bevacizumab, lenvatinib, or sorafenib, in 36 centers 4 countries (Italy, Japan, Republic Korea, and UK). The primary endpoint was overall survival (OS) bevacizumab versus lenvatinib. Secondary endpoints were progression-free (PFS) OS PFS...
Abstract Background Although atezolizumab plus bevacizumab (Atez/bev) treatment has been developed for unresectable hepatocellular carcinoma (u‐HCC), changes in hepatic function during therapy have yet to be reported. Aim This retrospective clinical study aimed elucidate early responses Atez/Bev. Methods From September 2020 April 2021, 171 u‐HCC patients undergoing Atez/Bev were enrolled (BCLC stage A:B:C:D = 5:68:96:2). Of those, 75 had no prior history of systemic treatment. Relative and...
Atezolizumab plus bevacizumab (Atez/Bev) treatment is recommended for unresechepatocellular carcinoma (u-HCC) patients classified as Child-Pugh A (CP-A). This study aimed to elucidate the prognosis of treated with Atez/Bev, especially CP-A and -B cases.From September 2020 March 2022, 457 u-HCC Atez/Bev were enrolled (median age 74 years, male:female = 368:89, CP-A:CP-B 427:30, score [CPS] 5:6:7:8:9 271:156:21:8:1). Therapeutic response was evaluated using RECIST ver.1.1. Clinical features...
To investigate whether neutrophil-to-lymphocyte ratio (NLR) can predict outcomes in patients with unresectable hepatocellular carcinoma (HCC) treated atezolizumab plus bevacizumab (Atez/Bev).A total of 249 HCC Atez/Bev were included. We analyzed survival and discontinuation this therapy cohort.Cumulative overall at 2, 4, 6, 8 months was 97.6%, 94.9%, 88.9%, 82.8%, respectively. Cumulative differed significantly between low (<3.0) versus high (≥3.0) NLR (P = 0.001). Conversely, cumulative...
The aim of this retrospective multicenter study was to clarify the antifibrotic effect and long-term outcome sodium glucose cotransporter 2 inhibitors (SGLT2-Is) in patients with nonalcoholic fatty liver disease (NAFLD) complicated by type diabetes mellitus (T2DM). Of 1262 consecutive T2DM who recently received SGLT2-Is, 202 NAFLD had been receiving SGLT2-Is for more than 48 weeks were subjected analysis. Furthermore, 109 on SGLT2-I therapy 3 years at time analysis assessed effects SGLT2-Is....
The aim of this retrospective proof-of-concept study was to compare different second-line treatments for patients with hepatocellular carcinoma and progressive disease (PD) after first-line lenvatinib or atezolizumab plus bevacizumab.A total 1381 had PD at therapy. 917 received as treatment, 464 bevacizumab first-line.49.6% a therapy without any statistical difference in overall survival (OS) between (20.6months) (15.7months; p = 0.12; hazard ratio [HR]= 0.80). After first-line, there wasn't...
Introduction: Lack of an established methodology for post-progression systemic treatment following atezolizumab plus bevacizumab (Atez/Bev) administration is important clinical issue. The present study aimed to elucidate the potential lenvatinib as a second-line option after Atez/Bev failure. Methods: From 2020 2022, 101 patients who received were enrolled (median 72 years, males 77, Child-Pugh A 82, BCLC-A:B:C:D = 1:35:61:4), while 29 treated with another molecular targeting agent (MTA)...
Background/Aim: Rapid development of systemic treatments has resulted in improved prognosis for unresectable hepatocellular carcinoma (uHCC) patients. Since immune therapy shows a favorable therapeutic efficacy, use tumor markers as biomarkers monitoring treatment response is necessary. This study aimed to elucidate changes positive rates 3 available Japan, including alpha-fetoprotein (AFP), des-gamma-carboxy prothrombin (DCP), and lens culinaris agglutinin-reactive AFP (AFP-L3) uHCC...
It was recently reported that hepatocellular carcinoma (HCC) patients with non-alcoholic steatohepatitis (NASH) are not responsive to immune-checkpoint inhibitor (ICI) treatment. The present study aimed evaluate the therapeutic efficacy of lenvatinib in fatty liver disease (NAFLD)/NASH-related unresectable-HCC (u-HCC). Five hundred thirty u-HCC Child-Pugh A were enrolled, and divided into NAFLD/NASH (n = 103) Viral/Alcohol 427) groups. Clinical features compared a retrospective manner....
A comparison of therapeutic efficacy between atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib treatment given as first-line therapy for unresectable hepatocellular carcinoma (u-HCC) in regard to progression-free survival (PFS) overall (OS) has not been reported. We aimed elucidate which those initial u-HCC greater prognostic impact on PFS OS affected patients, retrospectively.From 2020 January 2022, 251 (Child-Pugh A, ECOG PS 0/1, BCLC-B/C) treated were enrolled (Atez/Bev-group, n =...
The present study focused on the association of early bevacizumab (Bev) interruption with clinical outcome atezolizumab plus bevacizumab.This retrospective included 239 patients advanced hepatocellular carcinoma receiving atezolizumab/Bev from September 2020 to June 2021 at 16 different institutions in Japan. We conducted a 9-week landmark analysis investigate Bev due adverse events therapeutic efficacy.The median age was 73.0 (68.0-80.0) years old, 195 (81.6%) men. objective response rate...
The present study focused on Geriatric Nutritional Risk Index (GNRI), which is based bodyweight and serum albumin, known as an easy-to-use nutritional assessment tool in clinical settings, to elucidate the prognostic predictive ability of GNRI patients treated with atezolizumab plus bevacizumab (Atez/Bev) for hepatocellular carcinoma (HCC).A total 525 HCC Atez/Bev, their classification unsuitable status curative treatments and/or transarterial catheter chemoembolization, were enrolled...
To evaluate the efficacy and safety of oral semaglutide for type 2 diabetes mellitus (T2DM) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
Although systemic therapy is recommended for patients with multiple intermediate stage unresectable hepatocellular carcinoma (u-HCC) classified as beyond the up-to-7 criteria (UT-7 out/multiple) a transcatheter arterial chemoembolization (TACE) unsuitable condition, few reports have examined therapeutic efficacy of atezolizumab plus bevacizumab combination (Atez/Bev) in such cases. This study aimed to elucidate response Atez/Bev u-HCC UT-7 out/multiple.From September 2020 2021, 95 Japanese...
There is no standard posttreatment for patients with advanced hepatocellular carcinoma (HCC) in whom lenvatinib therapy has failed. This study aimed to investigate rates of migration after and explore candidates second-line agents the failed therapy.We retrospectively collected data on HCC who received as first-line agent 7 institutions.Overall survival progression-free (PFS) 178 were 13.3 months (95% confidence interval [CI], 11.5-15.2) 6.7 CI, 5.6-7.8), respectively. Sixty-nine 151 (45.7%)...
Abstract Aim The safety and efficacy of atezolizumab plus bevacizumab (Atez/Bev) in elderly patients with unresectable hepatocellular carcinoma (HCC) have not been sufficiently investigated. Methods A total 317 HCC treated Atez/Bev were studied. We compared the survival frequency adverse events versus non‐elderly who using an analysis inverse probability weighting (IPW). Results Univariate adjusted IPW showed that being is associated worse overall or progression‐free (hazard ratio [HR],...
Recently, the neo-Glasgow prognostic score (GPS), a composite biomarker determined by C-reactive protein level and albumin-bilirubin grade, was developed to predict outcomes in hepatocellular carcinoma (HCC) patients who undergo hepatic resection. The present research investigated whether neo-GPS could prognosis HCC treated with atezolizumab plus bevacizumab (Atez/Bev).A total of 421 were Atez/Bev investigated.Multivariate Cox hazards analysis showed that GPS 1 (hazard ratio (HR), 1.711; 95%...
Introduction: The prognostic nutritional index (PNI) is a multiparametric score introduced by Onodera based on the blood levels of lymphocytes and albumin in patients with gastrointestinal neoplasms. Regarding hepatocellular carcinoma (HCC), its role has been shown treated sorafenib lenvatinib. aim this real-world study was to investigate association between clinical outcomes PNI being atezolizumab plus bevacizumab. Methods: overall cohort multicentric included 871 consecutive HCC from 5...
Abstract Purpose: This study aimed to investigate the safety and efficacy of lenvatinib in real-world settings, including patients excluded from REFLECT trial, a phase III trial that compared with sorafenib. Patients Methods: multicenter, nonrandomized, open-label prospective was conducted at 10 medical facilities Japan (jRCTs031190017). Eligible had advanced hepatocellular carcinoma (HCC) were suitable for therapy. The included high tumor burden (with &gt;50% intrahepatic volume, main...